Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050531 | 0.84 | MAPK1 (0.47) | HRH1HRH4TDP2SRD5A2SRD5A1 | |
| SCHEMBL3044463 | 0.81 | MAPK1 (0.38) | HRH1HRH4TDP2SRD5A2SRD5A1 | |
| SCHEMBL3042897 | 0.71 | CYP2C9 (0.43) | HRH1HRH4SRD5A2SRD5A1ALDH1A1 | |
| SCHEMBL3036650 | 0.70 | MAPK1 (0.64) | HRH1HRH4SRD5A2SRD5A1LMNA | |
| SCHEMBL3042921 | 0.69 | HRH1 (0.42) | HRH1HRH4LMNA | |
| SCHEMBL3046574 | 0.69 | SRD5A1 (0.39) | HRH1SRD5A2SRD5A1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3044388 | 0.69 | HRH1 (0.42) | HRH1HRH4LMNA | |
| Hydrochloric Acid SCHEMBL3037285 | 0.68 | CYP2D6 (0.45) | HRH1HRH4SRD5A2ALDH1A1LMNA | |
| SCHEMBL3440731 | 0.67 | ALDH1A1 (0.69) | SRD5A2SRD5A1ALDH1A1KDM4EMAPT | |
| SCHEMBL31431434 | 0.67 | MAP3K14 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243778-B1 | PIPERIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| US-8377967-B2 | Piperidine derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20100331365-A1 | PIPERIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2243778-A1 | PIPERIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331365-A1 | PIPERIDINE DERIVATIVE | HRH4, HRH3, HRH2 | HRH1 4/4885HRH4 1/4885TDP2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.